AW: [rda-covid19-clinical] April 29 RDA Clinical Subgroup meeting on COVID-19

30 Apr 2020
Groups audience: 

Dear all,
yesterday in the telco in the clinical subgroup the topic of consent was mentioned.
I found an opinion of the European Data Protection Board (where the data protection authorities of the EU Member States and the European Data Protection Supervisor are assembled).
The opinion discusses issues related to consent and more general the legal basis for processing of personal data in the framework of clinical trials for medicinal products.
Since I am not a medical doctor, I cannot assess how useful the opinion for our group is, but I thought it could be good input to the discussion.
Best regards,
Diana Dimitrova
Von: ***@***.*** [mailto:***@***.***]
Gesendet: Dienstag, 28. April 2020 16:47
An: daweilin via RDA-COVID19-Clinical <***@***.***>
Betreff: [rda-covid19-clinical] April 29 RDA Clinical Subgroup meeting on COVID-19
Hi Subgroup,
Here is the agenda for tomorrow’s call.
1. Updates from RDA-COVID-19 WG call on Tuesday (April 28) (Dawei Lin)
2. Ideas to improve the clarity of the clinical group’s recommendations (two-page summary) and plans to generate a refined document by April 30 (Andrea Jackson-Dipina)
3. Solicit recommendations on consent issues and sharing imaging and immunological data. If you know somebody would like to contribute to those three areas, please let the moderators know and invite them to join the call tomorrow or join the Subgroup.
4. Open discussions on additional areas in the scope of the subgroup
The information for tomorrow’s teleconf:
Wednesday April 29 13.00 UTC (9am EST) Clinical sub-group meeting
Please join my meeting from your computer, tablet or smartphone.
Thank you,
Co-Moderators: Sergio Bonini (***@***.***), Andrea Jackson-Dipina (***@***.***), Dawei Lin (***@***.***)
Co-Chair Liaison: Anne Cambon-Thomsen (***@***.***
FIZ Karlsruhe - Leibniz-Institut für Informationsinfrastruktur GmbH.
Sitz der Gesellschaft: Eggenstein-Leopoldshafen, Amtsgericht Mannheim HRB 101892.
Geschäftsführerin: Sabine Brünger-Weilandt.
Vorsitzende des Aufsichtsrats: MinDirig’in Dr. Angelika Willms-Herget.
FIZ Karlsruhe ist zertifiziert mit dem Siegel "audit berufundfamilie".

File Attachment: 
PDF icon edpb_opinion_CTR.pdf176.67 KB

submit a comment